Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study
2024 ASCO Annual Meeting
Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The DEB study was a phase three clinical trial that was recently presented at the ASCO meeting. This study evaluated the combination of R-CHOP with HDAC inhibitor, Tucidinostat. In this trial, it was conducted exclusively in China and it enrolled patients in the frontline setting that had double expressor lymphoma.
Double expressor lymphoma is the specific subset of diffuse large B-cell lymphoma that shows increased expression of both MIC and BCL2 without the associated gene rearrangements. In this clinical trial, patients were randomized to either placebo or Tucidinostat in combination with R-CHOP, and they received that for six cycles and then went on to receive either maintenance therapy with Tucidinostat or placebo. The combination of Tucidinostat and R-CHOP in this clinical trial actually yielded increased CR rates compared to R-CHOP therapy alone, and additionally, this translated into an event-free survival benefit as well. Though there's only a short follow-up of approximately 13.9 months median at this point, and therefore we need longer followup to get a better understanding of outcomes.
Importantly, this study did not show a difference in overall survival at this point. The combination of Tucidinostat and R-CHOP was relatively well tolerated, though we did see a higher incidence of hematologic toxicity along with infectious complications compared to R-CHOP therapy alone.
This is overall my take on this is it's encouraging data, but we do need to have longer term followup. Additionally, questions do still remain regarding if this data is applicable to non-Asian populations, what's the impact of maintenance therapy in this clinical trial that was employed, and then, additionally, how do these results really compare to one of the other standards of care that we use in diffuse large B-cell lymphoma, which is Polatuzumab RCHP.
Related Videos
The ASCO Post Staff
Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).
The ASCO Post Staff
Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).
The ASCO Post Staff
Pauline Funchain, MD, of Stanford University and the Stanford Cancer Institute, and Paolo A. Ascierto, MD, of Italy’s Istituto Nazionale Tumori and IRCCS Fondazione G. Pascale, discuss efficacy and safety findings of the triplet therapy nivolumab, relatlimab-rmbw, and ipilimumab in patients with advanced melanoma (Abstract 9504).
The ASCO Post Staff
Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).
The ASCO Post Staff
Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as gene‐expression signatures for tumor‐induced proliferation, PD‐L1 status, or the mutation status of RCC driver genes.